📚 Hepatology — L1: Acute & Chronic Hepatitis

📚 Lecture Overview

This lecture covers acute and chronic hepatitis, detailing their etiology, clinical presentation, diagnostic evaluation, and management strategies. Understanding these concepts is critical because viral hepatitis and liver injury are major global causes of morbidity, cirrhosis, and hepatocellular carcinoma. Students must master how to differentiate between acute and chronic presentations and recognize the unique properties of Hepatitis A, B, and C.

🎯 Key Concepts & Definitions

• Acute Hepatitis: Acute inflammation of the hepatic parenchyma or injury to hepatocytes resulting in elevated liver enzymes (ALT, AST) lasting less than 6 months.
• Chronic Hepatitis: Hepatic inflammation and necrosis continuing for at least 6 months, leading progressively to architectural reorganization and cirrhosis if untreated.
• Hepatocellular Injury: Damage to liver cells marked by significantly elevated serum transaminases (ALT and AST).
• Synthetic Function: The liver's ability to produce vital proteins, measured reliably and quickly by Prothrombin time (PT) and INR.
• Sustained Virological Response (SVR): The clearance of HCV RNA, effectively representing a cure for Hepatitis C.
• Seroconversion: The period in Hepatitis B where antigens disappear and corresponding antibodies appear (e.g., HBeAg seroconversion).

📖 Main Content

I. Acute Hepatitis & Evaluation

• Definition & Histopathology:
• Defined as liver inflammation lasting < 6 months.
• Hallmark histological findings: hepatocyte necrosis/ballooning combined with inflammatory cell infiltrate.
• Clinical Presentation:
• Can range from asymptomatic liver function elevation to severe acute liver failure.
• Symptoms include unexplained fatigue, fever, anorexia, epigastric pain, dark urine, and icteric eyes.
• Markers of Injury and Failure:
• ALT and AST: Markers of hepatocyte damage. Massive elevations (> 15x ULN or > 10,000 U/L) point to drug toxicity, ischemia, or acute autoimmune/Wilson disease.
• PT/INR: The best marker for acute synthetic dysfunction. INR > 1.5 is a poor prognostic sign indicating impending acute liver failure.
• Bilirubin & Ammonia: Elevated due to impaired uptake/conjugation and failed detoxification.
• Albumin: Not useful for acute injury because it has a long half-life; low albumin indicates chronicity.
• Management of Acute Hepatitis:
• Supportive care for self-limited infections (HAV, HEV) resolving in 2–4 weeks.
• N-acetylcysteine (NAC): Used immediately for acute acetaminophen toxicity and all cases of acute liver failure (except ischemia).

II. Hepatitis A Virus (HAV)

• Virology & Transmission:
• Single-stranded, positive-sense RNA virus.
• Transmitted via the fecal-oral route.
• Outcomes & Diagnosis:
• Excellent prognosis with complete recovery in > 95% of cases, granting long-term immunity.
• HAV-IgM indicates acute infection; HAV-IgG indicates past infection or late acute infection.

III. Chronic Hepatitis

• Classification & Causes:
• Defined by inflammation lasting ≥ 6 months.
• Classified by cause, histologic activity (Metavir score), and stage of fibrosis.
• Major causes: Viral (HBV, HCV, HDV), Drugs, Alcoholic liver disease, Non-alcoholic steatohepatitis (NASH), Autoimmune, and Metabolic disorders (Wilson's disease, Hemochromatosis, Alpha-1 antitrypsin deficiency).
• Cirrhosis Suspicion Criteria:
• Platelets < 160,000
• AST > ALT level reversal
• Elevated bilirubin, decreased albumin, and prolonged PT/INR.

IV. Chronic Hepatitis C (HCV)

• Virology & Epidemiology:
• Small, single-stranded positive-sense enveloped RNA virus with 6 major genotypes (Genotype 4 is predominant in Egypt).
• 85% of acute cases progress to chronic hepatitis C.
• Diagnosis:
• HCV-Ab (ELISA): First test ordered; indicates exposure only, does not differentiate acute vs. chronic, and remains positive after cure. Must be confirmed with PCR.
• Quantitative PCR for HCV-RNA: Confirmatory test for active replication and baseline pre-treatment assessment.
• Treatment & Management:
• Curable disease using interferon-free Direct-Acting Antivirals (DAAs) with cure rates (SVR) of ≥ 95%.
• Treatment is recommended for all patients with HCV.
• Post-cure, cirrhotic patients must still undergo regular HCC screening (US abdomen ± AFP every 6 months) and variceal screening.

V. Chronic Hepatitis B (HBV)

• Virology & Transmission:
• Double-stranded DNA virus with intrinsic oncogenic properties (can cause HCC in non-cirrhotic patients).
• Transmitted parenterally, per-mucus, and vertically; highly infectious and can survive for 7 days outside the body.
• Treatment Goals:
• Antiviral treatment suppresses but does not eradicate HBV.
• Goals: suppress replication, reduce necroinflammation, and delay/prevent cirrhosis, liver failure, and HCC.
• Prevention & Vaccination:
• Recombinant vaccines administered in three doses at 0, 1, and 6 months.
• HBsAb ≥ 10 IU/ml indicates immunity; < 10 IU/ml indicates failure requiring revaccination.
• Hepatitis B Immune Globulin (HBIG) provides immediate passive immunity and is given with the vaccine to newborns of HBsAg-positive mothers (within 12 hours of birth) and after needle-stick exposures.

📊 Visual Learning

💡 Important Points to Remember

• Duration Threshold: The dividing line between acute and chronic hepatitis is strictly 6 months.
• The INR Warning: An INR > 1.5 signifies failing synthetic function and impending acute liver failure.
• Albumin vs. PT: PT/INR changes rapidly (hours/days) indicating acute synthetic failure, whereas low albumin reflects chronic liver disease.
• HCV Cure vs. HCC Risk: Eliminating HCV with DAAs yields a ≥ 95% cure rate, but cirrhotic patients remain at risk for HCC and require lifelong screening.
• HBV Eradication Myth: Antivirals for HBV suppress replication but do not eradicate the virus from the host.
• HCV Antibody Limitation: A positive HCV-Ab test only proves exposure; it cannot differentiate acute from chronic infection, nor does it prove active viremia (requires PCR).
• Acetaminophen Overdose: Treated with N-acetylcysteine (NAC) as early as possible.
• Perinatal HBV Prophylaxis: Infants of HBsAg-positive mothers must receive both the vaccine and HBIG at different sites within 12 hours of birth.
• Vaccine Protective Titer: Anti-HBs levels ≥ 10 IU/ml confirm immunity; levels < 10 IU/ml require revaccination.
• HBV Oncogenicity: Unlike HCV, HBV has direct oncogenic properties capable of causing hepatocellular carcinoma even in non-cirrhotic patients.
• Coinfection Danger: Patients co-infected with HBV, HDV, or HIV experience more rapidly progressive liver disease.

⚠️ Common Exam Questions & Traps

• MCQ Trap on HCV Antibody: Examiners love to trick students by stating "A patient has a positive HCV antibody test, therefore they currently have active chronic hepatitis C." False. HCV-Ab stays positive even after a successful cure or past cleared infection; active disease requires positive HCV-RNA PCR.
• MCQ Trap on Albumin in Acute Failure: Questions may ask which lab test best assesses sudden synthetic loss in acute toxicity. Students often choose albumin. False. Albumin has a long half-life; PT/INR is the correct marker for acute failure.
• Short Answer Trap on HBV Treatment: Examiners often ask if antiviral drugs cure/eradicate Hepatitis B. False. Antivirals suppress HBV DNA replication; they do not eradicate it.
• Clinical Scenario Trap: A patient cured of HCV via DAAs asks if they can stop all follow-up care because the virus is gone. False. If they have underlying cirrhosis, they must continue regular HCC and variceal screening.

📝 Quick Review Checklist

I can explain the difference between acute and chronic hepatitis based on duration and pathology
I understand why PT/INR is a marker of acute failure while albumin indicates chronicity
I can define the diagnostic sequence for Hepatitis C (HCV-Ab followed by quantitative PCR)
I know the standard cure rate and treatment modality for Hepatitis C (DAAs, ≥ 95%)
I understand that HBV treatment suppresses but does not eradicate the virus
I know the post-exposure and neonatal prophylaxis protocol for Hepatitis B (Vaccine + HBIG)
I can identify the protective antibody threshold for the Hepatitis B vaccine (≥ 10 IU/ml)
I know when to administer N-acetylcysteine in acute liver injury